Published in Hepatology on March 15, 2013
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open (2015) 1.43
Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol (2015) 0.80
Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. Can J Gastroenterol Hepatol (2014) 0.80
Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study. Curr Oncol (2016) 0.79
The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis (2017) 0.75
Pricey pills for an even pricier problem. Cancer (2015) 0.75
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag (2015) 0.75
Immune-Mediated Therapies for Liver Cancer. Genes (Basel) (2017) 0.75
Healthcare costs associated with hepatocellular carcinoma and the value of care. Hepatology (2013) 0.75
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med (2017) 0.75
Gastrointestinal Complications of Obesity. Gastroenterology (2017) 0.75
The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes. Can J Gastroenterol Hepatol (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med (2009) 6.46
Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol (2009) 4.39
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ (2004) 4.13
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol (2013) 3.70
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Physician factors associated with discussions about end-of-life care. Cancer (2010) 3.54
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis (2013) 3.27
30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst (2005) 3.26
How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) (2010) 3.24
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol (2008) 2.68
Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med (2008) 2.64
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Public participation in health care priority setting: A scoping review. Health Policy (2009) 2.52
Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA (2012) 2.47
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol (2003) 2.42
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
A Canadian screening program for hepatitis C: is now the time? CMAJ (2013) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology (2011) 2.26
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr (2010) 2.25
The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol (2005) 2.21
Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion (2007) 2.19
Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis (2011) 2.17
End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst (2011) 2.14
Integrating Physician Services in the Home: evaluation of an innovative program. Can Fam Physician (2010) 2.13
The half-cycle correction revisited: redemption of a kludge. Med Decis Making (2013) 2.11
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer (2010) 2.01
Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ (2009) 2.01
Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med (2013) 2.00
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med (2002) 1.90
Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol (2012) 1.90
Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med (2012) 1.86
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial. J Am Coll Cardiol (2003) 1.84
Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med (2004) 1.81
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology (2010) 1.80
Is there an optimal comorbidity index for prostate cancer? Cancer (2008) 1.80
Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics. Pediatr Blood Cancer (2010) 1.78
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol (2006) 1.75
Racial and ethnic differences in end-of-life care in fee-for-service Medicare beneficiaries with advanced cancer. J Am Geriatr Soc (2008) 1.74
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Comparison of prospective and retrospective indicators of the quality of end-of-life cancer care. J Clin Oncol (2008) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
The effect on survival of continuing chemotherapy to near death. BMC Palliat Care (2011) 1.66
Comparative operative outcomes of early and delayed cholecystectomy for acute cholecystitis: a population-based propensity score analysis. Ann Surg (2014) 1.65
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Hospital characteristics, clinical severity, and outcomes for surgical oncology patients. Surgery (2010) 1.62
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer (2012) 1.62
Recurrence of hepatocellular carcinoma. N Engl J Med (2008) 1.60
Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med (2006) 1.60
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest (2014) 1.57
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology (2014) 1.52
Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol (2010) 1.49
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol (2005) 1.47
Lower use of hospice by cancer patients who live in minority versus white areas. J Gen Intern Med (2007) 1.47